The First Real Longevity Drugs Are Getting Closer | Longevity News Roundup – Week 30, 2026
Shownotes
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
----------
Sponsor: FlexBeam
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.
Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.
Link: https://rechargehealthas.sjv.io/jRQyQ5
----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health.
- Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.
- Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.
- Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.
- Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.
- Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing.
----------
News & References:
- Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/
- Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/
- Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/
- Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/
- Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/